Using patient data to predict health events in scleroderma
Official title: Harnessing multivariate patient- and population-level disease trajectories to predict major clinical events in scleroderma
Funded at Johns Hopkins University · NIH-11042211 · Data updated 2026-11-12
This study is looking at how scleroderma affects people in different ways over time, so we can find patterns that help doctors give better, personalized care to patients.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Johns Hopkins University NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project start | March 15, 2022 |
| Project end | February 28, 2027 |
| Funding year | 2025 |
| Award (this year) | $169,411 |
| NIH project number | 5K24AR080217-04 |
| Project ID | NIH-11042211 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with scleroderma who are experiencing varying symptoms and disease progression.
✕Less likely to help
Patients with scleroderma who have stable disease and do not exhibit significant variability in their symptoms may not benefit from this research.
What this research studies
This research focuses on understanding how scleroderma, a complex autoimmune disease, affects patients differently over time. By analyzing detailed clinical data, the study aims to identify patterns in disease progression and the occurrence of major health events. The approach involves capturing individual patient trajectories and using advanced modeling techniques to predict outcomes based on shared characteristics among patients. This could help tailor treatments and improve patient care.
Why it matters
Potential benefit: If successful, this research could lead to more personalized treatment plans for scleroderma patients, improving their health outcomes.
How similar studies have gone: Previous research has shown promise in using patient data to improve understanding of autoimmune diseases, indicating that this approach could be effective.
Where this research is happening
-
Johns Hopkins University
Baltimore, United States Active
Researchers
- Principal investigator: Shah, Ami Aalok — Johns Hopkins University
- Study coordinator: Shah, Ami Aalok
Related research
Other NIH-funded projects on the same topics.
-
Angiogenesis imaging in scleroderma to track digital ulcers
A patient-friendly look at using a special imaging tracer to watch blood vessel growth in the hands of people with scleroderma to help manage digital ulcers.
-
Cell-level clues to skin scarring in systemic sclerosis and localized scleroderma
A study at the University of Pittsburgh is looking at how skin cells and their helpers change at the DNA level in adults and children with systemic sclerosis to find new targets to reduce scarring.
-
Pediatric Scleroderma: Mapping Cells and Tissues to Personalize Care
A study will map the different cell types and tissue patterns in skin from children with scleroderma to identify patient-specific disease subtypes that could guide targeted therapies.
-
CD38 and NAD metabolism in scleroderma (systemic sclerosis) fibrosis
This grant explores how changes in NAD metabolism related to CD38 and NNMT may drive scarring in systemic sclerosis and tests new ways to stop it.
-
ISG15-positive monocytes and SPP1 macrophages in scleroderma lung disease
This grant studies a specific immune cell pathway in systemic sclerosis with lung scarring to help predict how the disease progresses.
-
Autoantibodies define scleroderma subgroups with distinct cancer links
Researchers are studying how specific autoantibodies in scleroderma patients relate to cancer timing and risk.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.